Table I.
Exosomal biomarkers and early detection of pancreatic cancer.
| Disease | Study | Exosome isolation | Exosomal biomarkers | Sensitivity | Specificity |
|---|---|---|---|---|---|
| Primary pancreatic | Que et al (2013) | Ultracentrifugation | miR-21 | 95.5% | 81.5% |
| cancer | (77) | miR-17-5P | 72.7% | 92.6% | |
| Madhavan et al | Ultracentrifugation | miR-1246 | 100% | 80% | |
| (2015) (80) | and immunoaffinity | miR-4644 | |||
| miR-3976 | |||||
| miR-4306 | |||||
| Joshi et al (2015) | LSPR-based assay | miR-10b | Statistically | Statistically | |
| (79) | significant | significant | |||
| Melo et al (2015) (81) | Ultracentrifugation | GPC1 protein | 100% | 100% | |
| Pancreatic cancer | Costa-Silva et al | Ultracentrifugation | MIF | Statistically | Statistically |
| liver pre-metastasis | (2015) (8) | significant | significant | ||
| Hoshino et al | Ultracentrifugation | Integrins αvβ5 | Statistically | Statistically | |
| (2015) (11) | significant | significant |
LSPR, localized surface plasmon resonance; GPC1, glypican-1; MIF, migration inhibitory factor.